Fresenius Medical Care AG & Co. KGaA (DE:FME)
XETRA:FME
Want to see DE:FME full AI Analyst Report?
FME Stock Chart & Stats
€38.69
-€0.05(-0.11%)
At close: 4:00 PM EST
€38.69
-€0.05(-0.11%)
Day’s Range― - ―
52-Week Range€34.57 - €54.02
Previous CloseN/A
Volume12.09K
Average Volume (3M)529.60K
Market Cap
€10.81B
Enterprise Value€19.84B
Total Cash (Recent Filing)€1.24B
Total Debt (Recent Filing)€11.03B
Price to Earnings (P/E)22.5
Beta0.58
Next Earnings
Aug 05, 2026EPS Estimate
1.05Next Dividend Ex-DateN/A
Dividend Yield3.54%
Share Statistics
EPS (TTM)3.28
Shares Outstanding293,413,450
10 Day Avg. Volume492,004
30 Day Avg. Volume529,597
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.19Price Target Upside-1.29% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering11
EPS Forecast (FY)4
Revenue Forecast (FY)€19.31B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationSustained free cash flow near €1.8B and operating cash flow strength provide durable funding for capex, dividends, debt reduction, and strategic investments. High cash conversion (~65% of net income) supports financial flexibility across business cycles and cushions reimbursement pressures.
Improving Leverage / De‑risked Balance SheetDeclining leverage from ~1.03x to ~0.78x equity signals deliberate de‑risking and better capital structure. Lower relative debt improves interest coverage and strategic optionality, enabling continued investment in clinics and products while reducing refinancing and macro interest rate vulnerability.
Integrated Services And Products ModelOwning both clinics and product manufacturing creates recurring consumables demand and cross‑sell synergies, improving utilization of devices and stabilizing manufacturing volumes. This vertical integration yields stickier customer relationships and structural revenue resilience versus product‑only peers.
Bears Say
Stagnant Top‑line GrowthA flat-to-declining revenue trend constrains long‑term operating leverage and scale benefits, forcing reliance on cost control, price/reimbursement improvements, or M&A to drive growth. Over 2–6 months this structural weak top‑line limits upside potential and strategic flexibility.
Moderate Margins Versus Earlier PeaksMargins remain modest versus prior cycle highs, capping earnings and return on capital even as profitability improves. This leaves less buffer for adverse reimbursement or input cost shocks and reduces the pace at which cash flow growth translates into higher returns or accelerated deleveraging.
Exposure To Payor / Reimbursement RiskSignificant dependence on public and private payor reimbursement creates structural sensitivity to regulatory changes and contract negotiations. Over the medium term, adverse shifts in payor policy or reimbursement rates can materially affect volumes, pricing power, and margin sustainability.
FME FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was €34.57 and its highest was €54.02 in the past 12 months.
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
Fresenius Medical Care AG & Co. KGaA’s market cap is €10.81B.
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Aug 05, 2026 which is in 79 days.
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Fresenius Medical Care AG & Co. KGaA released its earnings results on May 05, 2026. The company reported €0.91 earnings per share for the quarter, missing the consensus estimate of €1.012 by -€0.102.
Is Fresenius Medical Care AG & Co. KGaA overvalued?
According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued.
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of €1.44 which represents an annual dividend yield of 3.54%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 1.05.
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
Fresenius Medical Care AG & Co. KGaA has 293,413,450 shares outstanding.
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Fresenius Medical Care AG & Co. KGaA reported an EPS of €0.91 in its last earnings report, missing expectations of €1.012. Following the earnings report the stock price went down -10.677%.
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€38.19 (-1.29% Downside)
€38.19 (-1.29% Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.79%
12-Months-Change
Fundamentals
Return on Equity
7.26%
Trailing 12-Months
Asset Growth
-7.64%
Trailing 12-Months
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
FME Stock 12 Month Forecast
Average Price Target
€38.19
▼(-1.29% Downside)
Technical Analysis
Options Prices
Currently, No data available
---